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Background Prostate cancer is an aging-related disease. As the result of the radiation are of 
STAMPEDE trial came out, major shifts in the use of local therapy (LT) are expected for men 
newly diagnosed with locally advanced and metastatic disease. This study aims to determine 
the role of patient age on LT. 
Methods We identified 6882 and 37382 locally advanced and metastatic prostate cancer 
diagnosed in 2004-2014 using the National Cancer Database (NCDB). We used logistic 
multivariable regression to determine the role of age in the receipt of prostate and/or pelvic 
radiation or radical prostatectomy after adjusting for demographic and clinical factors. 
Results Among patients with locally advanced disease, 3,559 (52%) patients received 
definitive local therapy as their first course of therapy, including 2508 (36%) radiation and 
1,323 (19%) radical prostatectomy (RP). Among patients newly diagnosed with M1 disease, 
2371 (6.3%) patients received definitive local therapy. 1873 (5.0%) and 537 (1.4%) patients 
received radiation therapy and RP respectively. In the multivariable analysis (MVA), adjusted 
for clinical characteristics and demographics, compared with men age <50 years, the odds 
ratios for receiving local treatment were 0.36 (95% CI: 0.26-0.48) and 0.48 (95% CI: 0.37-0.60) 
for men ≥70 in locally advanced and metastatic disease respectively. 
Conclusion We found that local therapy was undertaken in the majority of men with regional 
disease, and less common in the metastatic setting. Age was a major determinant of the receipt 
of any local therapy, as well as the selection of prostatectomy or radiation therapy. 
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By incidence and mortality prostate cancer is an aging-related disease1. Indeed, the 
median age at diagnosis and death from disease in the United States is 66 and 80 years, 
respectively.2 The widespread integration of screening of men with prostate-specific antigen 
(PSA) has resulted in the detection of early-stage cancers in many individuals, and led to a 
reduction in prostate cancer mortality.3,4 Nonetheless, prostate cancer remains the second-
leading cause of cancer related death among men. Patients diagnosed at a localized stage 
experience nearly 100% 5-year survival, while the majority those diagnosed at advanced or 
metastatic stage will eventually succumb to the disease.5,6 On this basis, efforts have been 
directed at both averting progression through local therapy, while developing increasingly 
efficacious treatments for advanced or metastatic disease. Within the past decade, systemic 
therapies including new generations of androgen receptor inhibitors7, docetaxel-based 
chemotherapy 8, and bone targeting agents9 have been shown to improve overall survival.  
At the same time, there has been sustained interest for local therapy to the prostate in 
those with advanced or metastatic disease. Recently, the radiation arm of the STAMPEDE 
trial reported a survival benefit with prostate radiotherapy in the subset of patients with low-
volume metastatic disease and has now been incorporated into major clinical practice 
guidelines including the National Comprehensive Cancer Network’s (NCCN).10 However, 
prior to this publication, level-one evidence has been lacking, and support for this practice 
has been offered by observational studies.11-17 On this basis, radiation with androgen 
deprivation therapy (ADT) has been recommended as a preferred initial strategy for patients 
with N1 disease with greater than 5 years of life expectancy or symptomatic disease. Yet, it is 
not known how commonly local therapy is given to patients with advanced disease, or which 
factors contribute to its selection. 
As major shifts in practice are expected for men newly diagnosed with metastatic 
disease, there are reasons to study the role of patient age and local therapy. Age is 
consistently a major driver for treatment decisions in the localized setting, including the use 
of radical prostatectomy versus radiation therapy.18-20 Young patients may be offered therapy 
seen as maximally aggressive due to fewer competing causes of death, and improved 
tolerability. Second, although a high level of evidence is now available to support local 
therapy with radiation for men with low-volume M1 disease, prostatectomy likely still 
remains in use, and it is not known how age or other factors affect. Therefore, we aimed to 
evaluate the role of age on the diagnosis and treatment of men with locally advanced and 
metastatic prostate cancer.  
 
Materials and Methods 
Data Source 
We performed a retrospective study using registry data from the National Cancer Database 
(NCDB). The NCDB is a joint program of the Commission on Cancer (CoC) and the American 
Cancer Society, and is the largest oncology database in the United States, containing 
approximately 70% of cancer patients nationwide. NCDB contains patient-level demographic 
information such as race, age, and insurance status. Regional-level education and household 
income information is available and is reported by U.S. postal zip code. The NCDB also 
contains details regarding disease characteristics (year of diagnosis, clinical stage, PSA at 




Men diagnosed with adenocarcinoma of the prostate (International Classification of 
diseases-O-3 code: C61.9) between 2004 and 2014 were included. Patients from before 2004 
were not included because PSA and Gleason score were not routinely collected. We included 
patients with valid age, clinical T category, clinical M category and clinical N category (Nx 
was considered as unknown, but not missing) at diagnosis. Men with prior cancers were 
excluded as prior cancers can influence a patient’s demographics and treatments. A patient 
exclusion schema is shown in the Supplemental Table. The final analytic cohort consisted of 
1,066,298 patients.  
 
Variables 
We regarded age as both a continuous variable (per 1 year), and grouped as follows to 
reflect common clinical thresholds, including a stratification at age 70 years as used in the 
STAMPEDE study: ages<50 years, 50 to 70 years, and ≥70 years at the time of diagnosis. 
Cancer stage was defined as distant metastatic (M1) or regional metastatic (N1). Local therapy 
was defined as radical prostatectomy (RP), brachytherapy, and/or EBRT (RT) targeted to the 
prostate as indicated by treatment recorded in the NCDB. Non-local therapy was defined as all 
the other treatment modalities including systemic therapy (ADT, active surveillance, and/or 
EBRT not targeted to the prostate). Other variables that were included in the analysis were 
clinical T stage (T1, T2, T3, and T4), clinical M stage (M0, M1), clinical N stage (N0/Nx, N1), 
biopsy Gleason Score (≤6, 7, ≥8), year of diagnosis (2004-2007, 2008-2011, 2012-2014), 
race/ethnicity (non-Hispanic white, non-Hispanic black, and other/unknown), high school 
education status, income status, insurance status, metropolitan status. The Charlson/Deyo 
Comorbidity Index (CCI) was categorized as 0, 1, and 2 per the NCDB participant user file. 
Facility characteristics included regions, types, and distance from facility.22,23 
 
Statistical analysis 
We compared differences in clinical and sociodemographic characteristics between age 
groups, categorical variables were compared with the chi-square test and continuous variables 
were compared with the Mann Whitney test. Among men diagnosed with prostate cancer, we 
first used logistic regression to determine the odds of advanced or metastatic disease by age 
groups, controlling for year of diagnosis, patient demographics, and facility characteristics. We 
further analyzed the likelihood of receiving any local treatment by age at diagnosis in lymph-
node positive patients (clinical N1M0 stage) and distant metastatic patients (clinical M1 stage) 
respectively, controlling for clinical and demographic characteristics. All analyses were 




Descriptive characteristics of the study population stratified by age are shown in Table 1. 
Overall, 72% of patients were non-Hispanic white, and 96% had insurance coverage. Median 
age in the overall cohort was 65 years (Interquartile range: 58-71). Of these men, 39,355 (4%) 
were age <50 at the time of diagnosis, 720,573 (68%) were at age 50 to 70, and 306370 (29%) 
were older than 70 years. The median PSA value was 6.1 (IQR: 4.5-9.9), and most patients 
were diagnosed with lower Gleason grade cancers (41% Gleason <=3+3). A total of 45202 
(4.2%) patients were diagnosed with metastatic disease (clinical M1 or N1 stage). These 
included, 38,120 (3.6%) were diagnosed with distant metastatic disease (M1), and 7082 (0.7%) 
were diagnosed with regional lymph-node metastasis (N1M0). Comparison of cancer 
characteristics by age group revealed higher PSA, Gleason score, and stage among patients 
aged ≥70 years at diagnosis (Table 1).  
In the multivariable regression of diagnosis with metastatic prostate cancer, patients aged 
≥70 had significantly greater odds (OR 2.13. 95% CI: 2.01-2.26) compared to patients aged 
<50. In addition, later year of diagnosis (2012-2014, OR: 2.33, 95%CI: 2.27-2.39) and 2008-
2011 (OR: 1.39, 95%CI: 1.35-1.42) were more likely to be diagnosed with metastatic disease 
compared to their counterpart of 2004-2007. Patients without any insurance had a significantly 
higher odds of diagnosed with metastatic disease (OR: 4.27, 95%CI: 4.08-4.47) compared to 
who had any insurance. Shorter distance from the treatment facility was associated with higher 
odds of diagnosed with metastatic disease (nearest quintiles vs. farthest quintiles, OR: 1.85, 
95%CI: 1.78-1.92).  
To further analyze the association of age at diagnosis with treatment modalities in 
metastatic prostate cancer, 6882 and 37382 patients with regional lymph-node positive (N1M0) 
disease and distant metastatic (M1) disease with known treatment information were identified 
from the entire cohort. Descriptive characteristics of the study population stratified by age are 
shown in Table 3. Among patients diagnosed with N1 disease, 68% of patients were non-
Hispanic white, and 93% had insurance coverage. Median age in the cohort was 65 (IQR: 59-
72). Of these men, 252 (4%) were age <50 at the time of diagnosis, 4352 (63%) were at age 50 
to 70, and 2278 (33%) were older than 70 years. The most frequent PSA value category was 
<20. In our cohort, 11% of patients were missing information on Gleason score, and the most 
frequent category was ≥8 (63%). 
 For distant metastatic cohort. 65% of patients were non-Hispanic white, and 92% had 
insurance coverage. Median age in the cohort was 70 (IQR: 61-79). Of these men, 1113 (4%) 
were age <50 at the time of diagnosis, 17308 (46%) were at age 50 to 70, and 18961 (33%) 
were older than 70 years. The most frequent PSA value category was >40. In our cohort, 31% 
of patients were missing information on Gleason score, and the most frequent category was ≥8 
(54%). 
Among patients with N1 disease, 3,559 (52%) patients received definitive local therapy as 
their first course of therapy, including 2508 (36%) radiation and 1,323 (19%) RP. We observed 
substantial variation in local therapy based on patients age (Fig 1); in general, older men were 
less likely to receive RP. The proportion of patients receiving RT remained steady before age 
85 years but decreased significantly after patients ≥85 years. In the multivariable analysis 
(MVA), adjusted for clinical characteristics and demographics, compared with men age <50 
years, the odds ratios for receiving local treatment were 0.36 (95% CI: 0.26-0.48), and 0.73(95% 
CI: 0.54-0.98) for men age ≥70 and 50-70 years, respectively. Patients diagnosed with clinical 
T3 stage had the highest likelihood of receiving LT (OR: 5.77, 95%CI: 3.99-8.33). Patients 
without any insurance had a significantly lower likelihood of receiving LT (OR: 0.55, 95%CI: 
0.42-0.72) compared to who had any insurance. Men with higher PSA values, Gleason score, 
non-Hispanic Black race, and those residing in the northeast also had lower odds of local 
treatment.  
Among patients newly diagnosed with M1 disease, 2371 (6.3%) patients received 
definitive local therapy. 1873 (5.0%) and 537 (1.4%) patients received radiation therapy and 
RP respectively. Unadjusted rates of local treatment were similar across all age categories (Fig 
1). In the MVA, adjusted for clinical characteristics and demographics, men age ≥70 (OR:0.48, 
0.37-0.60), men without any insurance (OR: 0.52, 95%CI: 0.41-0.66), were significantly less 
likely to receive LT compared with men age <50 years and men with any insurance coverage. 
Patients diagnosed with clinical T3 stage had the highest likelihood of receiving LT (OR: 2.43, 
95%CI: 2.04-2.87). Men with higher PSA values, Gleason score, non-Hispanic Black race, 
higher comorbidities lever, and those residing in lower income area also had lower odds of 
local treatment.  
 
Discussion 
Using hospital registry data from the NCDB, we evaluated national practice patterns 
among patients with regional and distant metastatic prostate cancer. We found that local therapy 
was undertaken in the majority of men with regional disease, and less common in the metastatic 
setting. However, when controlling for disease characteristics, age was a major determinant of 
the receipt of any local therapy, as well as the selection of prostatectomy or radiation therapy. 
Patients older than 70 years had a two-fold lower odds of receiving local therapy. Patients 
without insurance, higher comorbidity level were less likely to receive LT. In light of the recent 
maturation of new level 1 evidence supporting a survival benefit for men with low-volume 
metastatic disease, we believe these findings can shed light on the practice pattern of local 
treatment among different groups and may inform efforts to refine patient selection and 
improve overall accessibility. 
We found that the odds of LT were significantly lower in group older than 70. Multiple 
previous studies have similarly reported that older men were less likely to undergo the 
potentially curative treatments of RP or radiotherapy in localized settings.20,24 Seth et al.19 
analyzed the treatment pattern among high risk prostate cancer using CaPSURE data. They 
reported the odds ratios for receiving local treatment were 0.21 (95% CI, 0.15 to 0.28), and 
0.04 (95% CI, 0.03 to 0.06) for 66 to 75, and ≥75 years compared with men age ≤55 years 
adjusting for CAPRA score and year of treatment. However, despite the discrepancy of local 
therapy among older and younger patients, prior studies did not find a significant difference in 
outcomes. In the subgroup analysis of STAMPEDE trial, overall survival improvement of 
patients allocated radiotherapy was not significantly different between age <70 (HR 1.03, 
95%CI 0.86-1.24) and age ≥70 (HR 0.78, 95%CI 0.63-0.98).10 Chad et al.12 reported similar 
results of their study analyzing the impact of LT in nodal disease using SEER data. In their 
study, the effect of radiotherapy on overall survival did not differ significantly between age<70 
and ≥70 in cN+ cohort. While in pN+ cohort, despite a greater benefit of local therapy for 
patients aged <70 years was being observed, the OS benefit of local therapy remained 
significant for patients aged >=70 years (HR 0.63, 95% CI 0.50-0.78). Existing evidence 
cannot justify such a huge difference in treatment decision making in the current study. 
Observational data in our study cannot fully control factors that influence decision making. 
Thus, there might be alternative explanations for the treatment discrepancy among age, 
including patient preference and metastatic volume. The age of the patient may affect treatment 
preferences. Older patients may be more risk averse and less willing to sacrifice quality of life 
for prolongation of life.25 Also, the metastatic volume has been showing to be a vital 
determinant of outcome in several studies.10,26 It would be reasonable to believe it also has a 
significant impact on treatment decision. 
Despite no level 1 evidence, local prostate therapy was performed in a small but number 
of patients with metastatic disease. The increasing interest may be raised by the survival benefit 
being observed from other cancer entities when the primary tumor was surgically resected.27,28 
A biological basis to support such aggressive therapy may be related to the elimination of 
cytokine signaling, which may enhance metastatic seeding.29,30 In recent years, retrospective 
data have been shown the association of radiotherapy with overall survival benefits.12,17 
However, the radiation arm of the STAMPEDE trial reported no improve overall survival for 
unselected patients (HR 0.92, 95%CI 0·80–1.06) while it was improved in patients with low 
metastatic burden (HR 0·68, 95% CI 0·52–0·90).10 The effectiveness of other forms of local 
treatment, such as RP, remains unproven. A recent study using NCDB report a survival benefit 
with mPCa and RP, 3-yr survival probability of 78% (95% CI 73–83%) for RP vs. 48% (95% 
CI 47–49%) for the non-local therapy group.15 Another study using SEER reported similar 5-
yr survival benefit (RP vs. NTL: 67.4% vs. 22.5%).17 However, retrospective studies suffer 
from severe selection bias and may not be convincing enough. Patients who underwent local 
therapy could be highly selected. Even after multivariate analysis and propensity score 
matching, there may still exist unmeasured confounding factor, reducing the comparability 
between treatment groups. Development of new systemic therapies, such as docetaxel, 
abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium223, also provides physicians 
options other than LT. Prospective randomized clinical trials are needed to elucidate the use of 
local therapy in this setting. 
We found that LT was omitted in almost half of patients with nodal disease despite 
recommendation that patients with symptomatic disease and reported survival benefit from 
multiple retrospective studies. A recent study using NCDB reported outcomes of propensity-
matched node-positive patients treated with RT and ADT versus ADT alone.31 RT was 
associated with a 50% reduction in risk of 5-year all-cause mortality (71.5% vs. 53.2%; P 
< .001). Another analysis using SEER database showed local therapy (RP and/or RT) improved 
10-year overall survival (45% vs. 29%; P < .001) and cancer-specific survival (67% vs. 53%; 
P < .001) compared with no local therapy.12 Published guidelines recommend either RT with 
long-term androgen deprivation therapy (ADT) or long-term ADT alone in node-positive 
prostate cancer patients. However, our study finds that RT and RP are still uncommon treatment 
choices (36% and 19% of patients), despite promising results from retrospective series. High-
level evidence from formal prospective trials is urgently needed to address the effectiveness of 
LT and the selection of optimal candidates. 
 
Limitations 
This study has certain limitations. First, only Commission on Cancer-accredited facilities 
contributed to the NCDB data collection; thus, the sample was not population-based. Second, 
because our dataset was limited to patients diagnosed between 2004 and 2014, more recent 
practice pattern could not be observed. Third, owing to the retrospective nature of the study, 
confounding factors may exist that were not accounted for. Forth, because detailed data 
regarding metastatic number and sites for patients were not available, this information could 
not be factored into treatment consideration. In addition, patient-related factors, such as patient 
motivation itself or social support of caregivers or spouses, and treatment-related factors, such 
as side-effect and toxicity are not captured by the NCDB, which may affect treatment decision. 
Finally, although we have data about comorbidity, we do not know patients’ life expectancy or 
the presence of local symptoms which have an impact on treatment choice. 
With the publication of the STAMPEDE-RT trial, radiation with systemic therapy is now 
recommended as first line treatment for patients with low-volume (less than or equal to 4 
metastatic sites). Therefore, future opportunities to examine practice patterns in light of this 
information will be informative. Newer imaging modalities are redefining how prostate cancer 
is staged (for example PSMA based imaging). This might refine eligibility and change 
definitions of high and low volume cancer.  
 
Conclusion 
Using hospital registry data from the NCDB, we evaluated national practice patterns 
among patients with regional and distant metastatic prostate cancer. We found that local therapy 
was undertaken in the majority of men with regional disease, and less common in the metastatic 
setting. Age was a major determinant of the receipt of any local therapy, as well as the selection 
of prostatectomy or radiation therapy. Randomized trials are needed to refine patient selection 
and improve overall accessibility. 
 
Table 1. Demographics and Clinical Characteristics at Diagnosis of 1066298 Men with Prostate Cancer  
No. of Patients (%) 
 
Characteristic 






(n = 1066298) (n = 39355) (n = 720573) (n = 306370) P 
Year of Diagnosis 
    
<.001 
2004-2007 408260(38) 14861(38) 264166(37) 129233(42) 
 
2008-2011 414446(39) 16429(42) 287178(40) 110839(36) 
 
2012-2014 243592 (23) 8065 (20) 169229 (23) 66298 (22) 
 
PSA(IQR) 6.1(4.5, 9.9) 5.1 (3.6, 8.0) 5.8 (4.4, 8.9) 7.3 (5.0, 12.9) <.001 
<20 829760 (78) 31026 (79) 576439 (80) 222295 (73) 
 
20~40 44760 (4) 1337 (3) 25410 (4) 18013 (6) 
 
>40 64862 (6) 1910 (5) 37030 (5) 25922 (8) 
 
Missing 126916 (12) 5082 (13) 81694 (11) 40140 (13) 
 
cT stage 
    
<.001 
T1 658255 (62) 24454 (62) 453030 (63) 180771 (59) 
 
T2 262806 (25) 8617 (22) 169270 (23) 84919 (28) 
 
T3 31954 (3) 940 (2) 19881 (3) 11133 (4) 
 
T4 8562 (1) 281 (1) 3949 (1) 4332 (1) 
 
TX 104721 (10) 5063 (13) 74443 (10) 25215 (8) 
 
cM stage 
    
<.001 
M0 1028178 (96) 38218 (97) 702905 (98) 287055 (94) 
 
M1 38120 (4) 1137 (3) 17668 (2) 19315 (6) 
 
cN stage 
    
<.001 
N0&X 1048409 (98) 38633 (98) 710111 (99) 299665 (98) 
 
N1 17889 (2) 722 (2) 10462 (1) 6705 (2) 
 
Gleason Score 
    
<.001 
≤6 433726 (41) 19773 (50) 310620 (43) 103333 (34) . 
7 400249 (38) 13768 (35) 277426 (39) 109055 (36) 
 
≥8 156364 (15) 3049 (8) 85214 (12) 68101 (22) 
 
Missing 75959 (7) 2765 (7) 47313 (7) 25881 (8) 
 
Race 
    
<.001 
non-hispanic white 766082 (72) 23975 (61) 512586 (71) 229521 (75) 
 
non-hispanic black 144050 (14) 9333 (24) 104039 (14) 30678 (10) 
 
other/unknown 156166 (15) 6047 (15) 103948 (14) 46171 (15) 
 
Insurance Status 
    
<.001 
any insurance 1024630 (96) 37349 (95) 689367 (96) 297914 (97) 
 
uninsured 18289 (2) 1073 (3) 15128 (2) 2088 (1) 
 
Missing 23379 (2) 933 (2) 16078 (2) 6368 (2) 
 
Non–high school graduation, %a 
   
<.001 
≥29 153011 (14) 5653 (14) 102533 (14) 44825 (15) 
 
20–28.9 221367 (21) 7895 (20) 147614 (20) 65858 (22) 
 
14–19.9 239388 (22) 8265 (21) 159868 (22) 71255 (23) 
 
<14 414530 (39) 15929 (40) 284589 (39) 114012 (37) 
 
Missing 38002 (4) 1613 (4) 25969 (4) 10420 (3) 
 
Regional incomeb 
    
<.001 
<$30,000 123872 (12) 4308 (11) 82306 (11) 37258 (12) 
 
$30,000–$35,999 169186 (16) 5389 (14) 111809 (16) 51988 (17) 
 
$36,000–$45,999 277518 (26) 9440 (24) 184654 (26) 83424 (27) 
 
≥$46,000 457826 (43) 18606 (47) 315923 (44) 123297 (40) 
 
Missing 37896 (4) 1612 (4) 25881 (4) 10403 (3) 
 
Comorbidity 
    
<.001 
0 (None) 903383 (85) 35688 (91) 614057 (85) 253638 (83) 
 
1 138148 (13) 3282 (8) 92453 (13) 42413 (14) 
 
2 (Highest) 24767 (2) 385 (1) 14063 (2) 10319 (3) 
 
Population Density 
    
<.001 
Metro Counties 850458 (80) 33138 (84) 577457 (80) 239863 (78) 
 
Urban Counties 161510 (15) 4368 (11) 107272 (15) 49870 (16) 
 
Rural Counties 23158 (2) 601 (2) 14944 (2) 7613 (2) 
 
Missing 31172 (3) 1248 (3) 20900 (3) 9024 (3) 
 
Facility Characteristics 
     
Region 
    
<.001 
Northeast 225894 (21) 8483 (22) 151912 (21) 65499 (21) 
 
South 385570 (36) 15572 (40) 264708 (37) 105290 (34) 
 
Midwest 281096 (26) 9300 (24) 187812 (26) 83984 (27) 
 
West 173008 (16) 5270 (13) 116141 (16) 51597 (17) 
 
Missing 730 (0) 730 (2) 0 (0) 0 (0) 
 
Facility Type 
    
<.001 
CCP 96448 (9) 2286 (6) 56908 (8) 37254 (12) 
 
Comprehensive CCP 465142 (44) 13776 (35) 303666 (42) 147700 (48) 
 




109288 (10) 4540 (12) 75426 (10) 29322 (10) 
 
Missing 730 (0) 730 (2) 0 (0) 0 (0) 
 
Distance from facilityc 
    
<.001 
quintiles1 (nearest) 211947 (20) 6185 (16) 130836 (18) 74926 (24) 
 
quintiles2 212139 (20) 7119 (18) 137946 (19) 67074 (22) 
 
quintiles3 210563 (20) 7887 (20) 143422 (20) 59254 (19) 
 
quintiles4 211027 (20) 8383 (21) 146707 (20) 55937 (18) 
 
quintiles5 (farthest) 210988 (20) 9361 (24) 155634 (22) 45993 (15) 
 
Missing 9634 (1) 420 (1) 6028 (1) 3186 (1) 
 
Abbreviations: PSA, prostate-specific antigen; IQR, interquartile range; CCP, Community Cancer Program; cM1, clinically positive for 
metastasis; cN1, clinically positive lymph nodes. 
a Non-High school graduation level was derived from the number of adults in the patient’s zip code who did not graduate from high school. 
b Regional income was estimated by matching the patient’s zip code recorded at the time of diagnosis against files derived from the 2012 
American Community Survey data (spanning the years 2008-2012 and adjusted for 2012 inflation). 
c Distance from facility was defined as the distance (in miles) from the patient’s zip code centroid to the reporting facility’s 
street address. 
 
Table 2. Univariate and Multivariable Logistic Regression Analyses Predicting Diagnosed with Metastatic 





OR (95% CI) P 
 
OR (95% CI) P 
Age 
     
≥70 2.09 (1.97,2.22) <.001 
 
2.13 (2.01,2.26) <.001 
50-70 0.87 (0.82,0.92) <.001 
 





Year of Diagnosis 
     
2012-2014 2.25 (2.19,2.30) <.001 
 
2.33 (2.27,2.39) <.001 
2008-2011 1.32 (1.29,1.36) <.001 
 






     
Black (non-Hispanic) 1.61 (1.57,1.66) <.001 
 
1.33 (1.29,1.37) <.001 
Other/unknown 1.17 (1.14,1.20) <.001 
 
1.07 (1.04,1.10) <.001 





     
Uninsured 3.94 (3.77,4.12) <.001 
 
4.27 (4.08,4.47) <.001 




Non–high school graduation, %a 
    
≥29 1.72 (1.68,1.77) <.001 
 
1.32 (1.26,1.37) <.001 
20–28.9 1.33 (1.30,1.37) <.001 
 
1.17 (1.13,1.21) <.001 
14–19.9 1.20 (1.17,1.24) <.001 
 






     
<$30,000 1.74 (1.69,1.79) <.001 
 
1.26 (1.21,1.31) <.001 
$30,000–$35,999 1.35 (1.31,1.39) <.001 
 
1.15 (1.11,1.19) <.001 
$36,000–$45,999 1.25 (1.22,1.28) <.001 
 






     
2 (Highest) 3.04 (2.92,3.17) <.001 
 
2.37 (2.27,2.48) <.001 
1 1.26 (1.23,1.30) <.001 
 
1.15 (1.12,1.18) <.001 





     
Urban Counties 0.96 (0.93,0.98) 0.001 
 
1.04 (1.01,1.08) <.001 
Rural Counties 0.98 (0.92,1.05) 0.58 
 
1.12 (1.04,1.20) <.001 





     
Region 
     
Northeast 0.98 (0.95,1.01) 0.26 
 
0.88 (0.85,0.91) <.001 
South 0.92 (0.89,0.95) <.001 
 
0.78 (0.76,0.80) <.001 
Midwest 1.00 (0.97,1.04) 0.81 
 






     
CCP 1.48 (1.42,1.54) <.001 
 
1.19 (1.14,1.25) <.001 
CCP Conprehensive 1.01 (0.97,1.04) 0.70 
 
0.98 (0.94,1.01) 0.20 
Academic/research 1.05 (1.02,1.09) 0.01 
 
1.09 (1.05,1.13) <.001 




Distance from facilityc 
     
quintiles1 (nearest) 2.06 (2.00,2.13) <.001 
 
1.85 (1.78,1.92) <.001 
quintiles2 1.59 (1.53,1.64) <.001 
 
1.56 (1.50,1.62) <.001 
quintiles3 1.29 (1.25,1.34) <.001 
 
1.35 (1.30,1.40) <.001 
quintiles4 1.20 (1.16,1.25) <.001 
 
1.23 (1.18,1.28) <.001 




Abbreviations: PSA, prostate-specific antigen; IQR, interquartile range; CCP, Community Cancer Program; cM1, clinically positive for 
metastasis; cN1, clinically positive lymph nodes. 
a Non-High school graduation level was derived from the number of adults in the patient’s zip code who did not graduate from high school. 
b Regional income was estimated by matching the patient’s zip code recorded at the time of diagnosis against files derived from the 2012 
American Community Survey data (spanning the years 2008-2012 and adjusted for 2012 inflation). 
c Distance from facility was defined as the distance (in miles) from the patient’s zip code centroid to the reporting facility’s street address. 
 
Table 3. Demographics and Clinical Characteristics at Diagnosis of 6882 Men with Node-Positive Prostate 
Cancer  
No. of Patients (%) 
 
Characteristic All Ages Age <50 years Age 50-70 years Age ≥70 
 
(n = 6882) (n = 252) (n = 4352) (n = 2278) P 
Radiation Therapy 
    
0.041 
Yes 2508 (36) 84 (33) 1634 (38) 790 (35) 
 
No 4374 (64) 168 (67) 2718 (62) 1488 (65) 
 
Radical Prostatectomy 
    
<0.001 
Yes 1323 (19) 99 (39) 1075 (25) 149 (7) 
 
No 5559 (81) 153 (61) 3277 (75) 2129 (93) 
 
PSA 
    
<0.001 
<20 3286 (48) 99 (39) 2144 (49) 1043 (46) 
 
20~40 1178 (17) 46 (18) 734 (17) 398 (17) 
 
>40 1869 (27) 89 (35) 1148 (26) 632 (28) 
 
Missing 549 (8) 18 (7) 326 (7) 205 (9) 
 
T stage 
    
<0.001 
T1 1607 (23) 46 (18) 1015 (23) 546 (24) 
 
T2 2098 (30) 65 (26) 1370 (31) 663 (29) 
 
T3 2146 (31) 94 (37) 1433 (33) 619 (27) 
 
T4 768 (11) 36 (14) 411 (9) 321 (14) 
 
TX 263 (4) 11 (4) 123 (3) 129 (6) 
 
Gleason Score 
    
<0.001 
≤6 319 (5) 15 (6) 203 (5) 101 (4) 
 
7 1475 (21) 60 (24) 1047 (24) 368 (16) 
 
≥8 4357 (63) 152 (60) 2717 (62) 1488 (65) 
 
Missing 731 (11) 25 (10) 385 (9) 321 (14) 
 
Year of Diagnosis 
    
0.014 
2004-2007 2004 (29) 79 (31) 1279 (29) 646 (28) 
 
2008-2011 2555 (37) 106 (42) 1638 (38) 811 (36) 
 
2012-2014 2323 (34) 67 (27) 1435 (33) 821 (36) 
 
Race 
    
<0.001 
non-hispanic white 4700 (68) 152 (60) 2895 (67) 1653 (73) 
 
non-hispanic black 1092 (16) 58 (23) 770 (18) 264 (12) 
 
other/unknown 1090 (16) 42 (17) 687 (16) 361 (16) 
 
Insurance Status 
    
<0.001 
any insurance 6396 (93) 221 (88) 3978 (91) 2197 (96) 
 
uninsured 286 (4) 21 (8) 230 (5) 35 (2) 
 
Missing 200 (3) 10 (4) 144 (3) 46 (2) 
 
Non–high school graduation, % 
   
0.012 
≥29 1168 (17) 42 (17) 790 (18) 336 (15) 
 
20–28.9 1343 (20) 49 (19) 866 (20) 428 (19) 
 
14–19.9 1565 (23) 53 (21) 984 (23) 528 (23) 
 
<14 2534 (37) 101 (40) 1538 (35) 895 (39) 
 
Missing 272 (4) 7 (3) 174 (4) 91 (4) 
 
Regional income 
    
0.006 
<$30,000 935 (14) 37 (15) 629 (14) 269 (12) 
 
$30,000–$35,999 1101 (16) 30 (12) 705 (16) 366 (16) 
 
$36,000–$45,999 1789 (26) 53 (21) 1129 (26) 607 (27) 
 
≥$46,000 2786 (40) 125 (50) 1716 (39) 945 (41) 
 
Missing 271 (4) 7 (3) 173 (4) 91 (4) 
 
Comorbidity 
    
<0.001 
0 (None) 5754 (84) 233 (92) 3645 (84) 1876 (82) 
 
1 911 (13) 17 (7) 595 (14) 299 (13) 
 
2 (Highest) 217 (3) 2 (1) 112 (3) 103 (5) 
 
Population Density 
    
0.404 
Metro Counties 5492 (80) 212 (84) 3476 (80) 1804 (79) 
 
Urban Counties 1027 (15) 29 (12) 639 (15) 359 (16) 
 
Rural Counties 145 (2) 4 (2) 100 (2) 41 (2) 
 
Missing 218 (3) 7 (3) 137 (3) 74 (3) 
 
Facility Characteristics 
     
Region 
    
<0.001 
Northeast 1557 (23) 67 (27) 957 (22) 533 (23) 
 
South 2171 (32) 77 (31) 1410 (32) 684 (30) 
 
Midwest 1892 (27) 65 (26) 1171 (27) 656 (29) 
 
West 1253 (18) 34 (13) 814 (19) 405 (18) 
 
Missing 9 (0) 9 (4) 0 (0) 0 (0) 
 
Facility Type 
    
<0.001 
CCP 676 (10) 26 (10) 401 (9) 249 (11) 
 
CCP Comprehensive 2702 (39) 75 (30) 1673 (38) 954 (42) 
 
Academic/research 2886 (42) 123 (49) 1896 (44) 867 (38) 
 
Integrated cancer program 609 (9) 19 (8) 382 (9) 208 (9) 
 
Missing 9 (0) 9 (4) 0 (0) 0 (0) 
 
Distance form facility 
    
<0.001 
quintiles1 (nearest) 1561 (23) 46 (18) 918 (21) 597 (26) 
 
quintiles2 1321 (19) 52 (21) 789 (18) 480 (21) 
 
quintiles3 1289 (19) 47 (19) 797 (18) 445 (20) 
 
quintiles4 1338 (19) 56 (22) 887 (20) 395 (17) 
 
quintiles5 (farthest) 1292 (19) 49 (19) 913 (21) 330 (14) 
 
Missing 81 (1) 2 (1) 48 (1) 31 (1) 
 
Abbreviations: PSA, prostate-specific antigen; IQR, interquartile range; CCP, Community Cancer Program; cM1, clinically positive for 
metastasis; cN1, clinically positive lymph nodes. 
a Non-High school graduation level was derived from the number of adults in the patient’s zip code who did not graduate from high school. 
b Regional income was estimated by matching the patient’s zip code recorded at the time of diagnosis against files derived from the 2012 
American Community Survey data (spanning the years 2008-2012 and adjusted for 2012 inflation). 
c Distance from facility was defined as the distance (in miles) from the patient’s zip code centroid to the reporting facility’s street address. 
 
Table 4. Demographics and Clinical Characteristics at Diagnosis of 37382 Men with Distant Metastatic 
Prostate Cancer  
No. of Patients (%) 
 
Characteristic 
All Ages Age <50 years Age 50-70 years Age ≥70 
 
(n = 37382) (n = 1113) (n = 17308) (n = 18961) P 
Radiation Therapy 
    
<.001 
Yes 1873 (5) 63 (6) 1055 (6) 755 (4) 
 
No 35509 (95) 1050 (94) 16253 (94) 18206 (96) 
 
Radical Prostatectomy 
   
<.001 
Yes 537 (1) 34 (3) 415 (2) 88 (0) 
 
No 36845 (99) 1079 (97) 16893 (98) 18873 (100) 
 
PSA 
    
<.001 
<20 8400 (22) 239 (21) 3970 (23) 4191 (22) 
 
20~40 4424 (12) 118 (11) 2001 (12) 2305 (12) 
 
>40 20009 (54) 642 (58) 9527 (55) 9840 (52) 
 
Missing 4549 (12) 114 (10) 1810 (10) 2625 (14) 
 
T stage 
    
<.001 
T1 8999 (24) 236 (21) 4284 (25) 4479 (24) 
 
T2 8292 (22) 230 (21) 3914 (23) 4148 (22) 
 
T3 4331 (12) 160 (14) 2257 (13) 1914 (10) 
 
T4 5038 (13) 179 (16) 2375 (14) 2484 (13) 
 
TX 10722 (29) 308 (28) 4478 (26) 5936 (31) 
 
N stage 
    
<.001 
N0&X 26760 (72) 659 (59) 11432 (66) 14669 (77) 
 
N1 10622 (28) 454 (41) 5876 (34) 4292 (23) 
 
Gleason Score 
    
<.001 
≤6 1028 (3) 35 (3) 458 (3) 535 (3) 
 
7 4384 (12) 141 (13) 2217 (13) 2026 (11) 
 
≥8 20285 (54) 613 (55) 9836 (57) 9836 (52) 
 
Missing 11685 (31) 324 (29) 4797 (28) 6564 (35) 
 
Year of Diagnosis 
    
0.01 
2004-2007 10270 (27) 358 (32) 4436 (26) 5476 (29) 
 
2008-2011 13686 (37) 447 (40) 6457 (37) 6782 (36) 
 
2012-2014 13426 (36) 308 (28) 6415 (37) 6703 (35) 
 
Race 
    
<.001 
non-hispanic white 24200 (65) 588 (53) 10234 (59) 13378 (71) 
 
non-hispanic black 7432 (20) 307 (28) 4339 (25) 2786 (15) 
 
other/unknown 5750 (15) 218 (20) 2735 (16) 2797 (15) 
 
Insurance Status 
    
<.001 
any insurance 34283 (92) 926 (83) 15074 (87) 18283 (96) 
 
uninsured 2250 (6) 152 (14) 1768 (10) 330 (2) 
 
Missing 849 (2) 35 (3) 466 (3) 348 (2) 
 
Non–high school graduation, % 
   
<.001 
≥29 7626 (20) 254 (23) 4004 (23) 3368 (18) 
 
20–28.9 8594 (23) 255 (23) 4077 (24) 4262 (22) 
 
14–19.9 8205 (22) 240 (22) 3568 (21) 4397 (23) 
 
<14 11608 (31) 315 (28) 5015 (29) 6278 (33) 
 
Missing 1349 (4) 49 (4) 644 (4) 656 (3) 
 
Regional income 
    
<.001 
<$30,000 6309 (17) 209 (19) 3207 (19) 2893 (15) 
 
$30,000–$35,999 6671 (18) 195 (18) 3152 (18) 3324 (18) 
 
$36,000–$45,999 10082 (27) 279 (25) 4589 (27) 5214 (28) 
 
≥$46,000 12976 (35) 381 (34) 5720 (33) 6875 (36) 
 
Missing 1344 (4) 49 (4) 640 (4) 655 (3) 
 
Comorbidity 
    
<.001 
0 (None) 29190 (78) 993 (89) 14159 (82) 14038 (74) 
 
1 5728 (15) 89 (8) 2294 (13) 3345 (18) 
 
2 (Highest) 2464 (7) 31 (3) 855 (5) 1578 (8) 
 
Population Density 
    
0.27 
Metro Counties 29966 (80) 900 (81) 13928 (80) 15138 (80) 
 
Urban Counties 5352 (14) 144 (13) 2475 (14) 2733 (14) 
 
Rural Counties 813 (2) 28 (3) 356 (2) 429 (2) 
 
Missing 1251 (3) 41 (4) 549 (3) 661 (3) 
 
Facility Characteristics 
    
Region 
    
<.001 
Northeast 7931 (21) 191 (17) 3489 (20) 4251 (22) 
 
South 12998 (35) 415 (37) 6474 (37) 6109 (32) 
 
Midwest 10255 (27) 303 (27) 4426 (26) 5526 (29) 
 
West 6172 (17) 178 (16) 2919 (17) 3075 (16) 
 
Missing 26 (0) 26 (2) 0 (0) 0 (0) 
 
Facility Type 
    
<.001 
CCP 4758 (13) 130 (12) 1973 (11) 2655 (14) 
 
CCP Comprehensive 15627 (42) 372 (33) 6648 (38) 8607 (45) 
 
Academic/research 13324 (36) 492 (44) 6985 (40) 5847 (31) 
 
Integrated cancer program 3647 (10) 93 (8) 1702 (10) 1852 (10) 
 
Missing 26 (0) 26 (2) 0 (0) 0 (0) 
 
Distance form facility 
   
<.001 
quintiles1 (nearest) 10821 (29) 238 (21) 4605 (27) 5978 (32) 
 
quintiles2 8374 (22) 236 (21) 3746 (22) 4392 (23) 
 
quintiles3 6667 (18) 212 (19) 3192 (18) 3263 (17) 
 
quintiles4 6088 (16) 198 (18) 2992 (17) 2898 (15) 
 
quintiles5 (farthest) 4878 (13) 209 (19) 2548 (15) 2121 (11) 
 
Missing 554 (1) 20 (2) 225 (1) 309 (2) 
 
Abbreviations: PSA, prostate-specific antigen; IQR, interquartile range; CCP, Community Cancer Program; cM1, clinically 
positive for metastasis; cN1, clinically positive lymph nodes. 
a Non-High school graduation level was derived from the number of adults in the patient’s zip code who did not graduate 
from high school. 
b Regional income was estimated by matching the patient’s zip code recorded at the time of diagnosis against files derived 
from the 2012 American Community Survey data (spanning the years 2008-2012 and adjusted for 2012 inflation). 







Figure 1. The utilization of local therapy in node-positive and distant metastatic prostate cancer 
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Table 5. Univariate and Multivariable Logistic Regression Analyses Predicting Local Therapy in 6882 Men with 




Characteristics Num % LT OR (95% CI) P 
 
OR (95% CI) P 
Age 
       
≥70 2098 40% 0.41 (0.31,0.54) <0.001 
 
0.36 (0.26,0.48) <0.001 
50-70 3956 59% 0.86 (0.65,1.13) 0.283 
 
0.73 (0.54,0.98) 0.035 





       
T1 1487 50% 4.52 (3.19,6.40) <0.001 
 
3.02 (2.09,4.37) <0.001 
T2 1916 53% 5.22 (3.69,7.38) <0.001 
 
3.53 (2.45,5.10) <0.001 
T3 1940 65% 8.33 (5.89,11.78) <0.001 
 
5.77 (3.99,8.33) <0.001 
T4 701 35% 2.46 (1.70,3.55) <0.001 
 
2.02 (1.37,2.98) <0.001 





       
<20 3013 61% 2.38 (2.10,2.68) <0.001 
 
2.26 (1.99,2.57) <0.001 
20~40 1104 54% 1.78 (1.52,2.07) <0.001 
 
1.76 (1.50,2.06) <0.001 
Missing 432 39% 0.96 (0.78,1.19) 0.725 
 
1.20 (0.95,1.52) 0.125 





       
≤6 286 55% 1.05 (0.83,1.34) 0.676 
 
1.11 (0.86,1.43) 0.430 
7 1344 60% 1.29 (1.14,1.47) <0.001 
 
1.23 (1.07,1.40) 0.003 
Missing 596 32% 0.42 (0.35,0.50) <0.001 
 
0.66 (0.54,0.81) <0.001 




Year of Diagnosis 
       
2012-2014 2141 53% 1.19 (1.05,1.35) 0.007 
 
1.36 (1.19,1.56) <0.001 
2008-2011 2325 55% 1.25 (1.11,1.42) <0.001 
 
1.38 (1.21,1.57) <0.001 





       
Black (non-
Hispanic) 
1013 46% 0.72 (0.63,0.82) <0.001 
 
0.76 (0.66,0.89) <0.001 
Other/unknown 980 53% 0.96 (0.84,1.10) 0.557 
 
1.07 (0.92,1.24) 0.403 
White (non-
Hispanic) 





       
Uninsured 274 39% 0.57 (0.45,0.73) <0.001 
 
0.55 (0.42,0.72) <0.001 






      
≥29 1090 51% 0.92 (0.80,1.06) 0.249 
   
20–28.9 1300 53% 0.96 (0.84,1.10) 0.554 
   
14–19.9 1503 53% 0.97 (0.85,1.10) 0.604 
   
<14 2348 54% ref 
    
Regional income 
       
<$30,000 893 52% 0.90 (0.77,1.05) 0.173 
   
$30,000–$35,999 1056 54% 0.99 (0.85,1.14) 0.844 
   
$36,000–$45,999 1700 50% 0.86 (0.76,0.97) 0.016 
   
≥$46,000 2628 54% ref 
    
Comorbidity 
       
2 (Highest) 207 40% 0.58 (0.44,0.77) <0.001 
   
1 847 54% 1.04 (0.90,1.20) 0.611 
   
0 (None) 5223 53% ref 
    
Population Density 
       
Urban Counties 969 55% 1.13 (0.99,1.30) 0.076 
   
Rural Counties 140 53% 1.03 (0.73,1.44) 0.879 
   
Metro Counties 5168 52% ref 
    
Facility 
Characteristics 
       
Region 
       
Northeast 1431 56% 1.22 (1.04,1.42) 0.015 
 
1.31 (1.11,1.55) 0.002 
South 1954 52% 1.04 (0.90,1.21) 0.588 
 
1.21 (1.03,1.42) 0.021 
Midwest 1772 52% 1.04 (0.90,1.21) 0.582 
 
1.13 (0.97,1.33) 0.125 





       
CCP 615 51% 1.04 (0.82,1.30) 0.770 
   
Comprehensive 
CCP 
2504 51% 1.03 (0.86,1.24) 0.761 
   
Academic/research 2592 55% 1.19 (0.99,1.43) 0.059 
   
Integrated cancer 
program 
566 51% ref 
    
Distance from 
facility 
       
quintiles1 (nearest) 1469 49% 0.70 (0.60,0.82) <0.001 
   
quintiles2 1228 52% 0.78 (0.66,0.92) 0.003 
   
quintiles3 1195 52% 0.81 (0.69,0.95) 0.010 
   
quintiles4 1232 54% 0.87 (0.74,1.02) 0.090 
   
quintiles5 
(farthest) 
1153 58% ref 







Table 6. Univariate and Multivariable Logistic Regression Analyses Predicting Local Therapy in 37382 Men with 




Characteristics Num %  LT OR (95% CI) P 
 
OR (95% CI) P 
Age 
       
≥70 17605 4% 0.49 (0.39,0.61) <.001 
 
0.48 (0.37,0.60) <.001 
50-70 15912 8% 0.95 (0.76,1.19) 0.655 
 
0.91 (0.72,1.15) 0.442 





       
T1 8395 8% 2.88 (2.49,3.32) <.001 
 
1.58 (1.35,1.86) <.001 
T2 7668 7% 2.72 (2.35,3.15) <.001 
 
1.67 (1.42,1.96) <.001 
T3 3966 10% 3.74 (3.19,4.39) <.001 
 
2.42 (2.04,2.87) <.001 
T4 4631 7% 2.64 (2.24,3.11) <.001 
 
2.06 (1.73,2.45) <.001 





       
N1 9844 6% 0.99 (0.90,1.08) 0.760 
   
N0&X 24665 6% ref 
    
PSA 
       
<20 7739 14% 4.53 (4.10,5.02) <.001 
 
3.82 (3.44,4.24) <.001 
20~40 4088 7% 2.12 (1.84,2.45) <.001 
 
1.91 (1.65,2.21) <.001 
Missing 4092 5% 1.36 (1.15,1.60) <.001 
 
1.59 (1.34,1.89) <.001 





       
≤6 954 17% 2.68 (2.25,3.21) <.001 
 
2.31 (1.91,2.80) <.001 
7 4056 10% 1.55 (1.38,1.74) <.001 
 
1.58 (1.40,1.78) <.001 
Missing 10687 3% 0.38 (0.33,0.43) <.001 
 
0.61 (0.53,0.70) <.001 




Year of Diagnosis 
       
2012-2014 12553 6% 0.83 (0.75,0.93) 0.001 
 
1.03 (0.91,1.16) 0.671 
2008-2011 12643 7% 1.06 (0.95,1.17) 0.317 
 
1.19 (1.06,1.33) 0.003 





       
Black (non-Hispanic) 6915 5% 0.75 (0.67,0.84) <.001 
 
0.85 (0.75,0.97) 0.014 
Other/unknown 5259 6% 0.87 (0.77,0.99) 0.029 
 
0.95 (0.83,1.08) 0.400 
White (non-
Hispanic) 





       
Uninsured 2121 4% 0.53 (0.42,0.67) <.001 
 
0.52 (0.41,0.66) <.001 




Non–high school graduation, % 
      
≥29 7297 5% 0.74 (0.66,0.84) <.001 
   
20–28.9 8234 6% 0.85 (0.76,0.95) 0.005 
   
14–19.9 7868 6% 0.88 (0.78,0.98) 0.023 
   
<14 11110 7% ref 
    
Regional income 
       
<$30,000 6042 5% 0.72 (0.63,0.82) <.001 
 
0.84 (0.73,0.97) 0.018 
$30,000–$35,999 6419 6% 0.76 (0.67,0.86) <.001 
 
0.82 (0.72,0.94) 0.003 
$36,000–$45,999 9693 6% 0.86 (0.78,0.96) 0.006 
 
0.92 (0.82,1.02) 0.118 





       
2 (Highest) 2328 3% 0.41 (0.32,0.52) <.001 
 
0.57 (0.44,0.72) <.001 
1 5378 5% 0.67 (0.59,0.76) <.001 
 
0.74 (0.65,0.85) <.001 





       
Urban Counties 5133 7% 1.11 (0.99,1.25) 0.086 
   
Rural Counties 787 5% 0.86 (0.63,1.17) 0.332 
   
Metro Counties 28589 6% ref 
    
Facility Characteristics 
      
Region 
       
Northeast 7327 7% 1.01 (0.88,1.16) 0.897 
   
South 11877 7% 1.04 (0.91,1.18) 0.556 
   
Midwest 9684 6% 0.92 (0.80,1.05) 0.211 
   
West 5621 6% ref 
    
Facility Type 
       
Community 4427 7% 1.23 (1.02,1.49) 0.034 
   
Comprehensive 14471 6% 1.15 (0.97,1.35) 0.104 
   
Academic/research 12188 7% 1.32 (1.12,1.55) 0.001 
   
Integrated cancer 
program 
3423 5% ref 
    
Distance from 
facility 
       
quintiles1 (nearest) 10155 5% 0.75 (0.65,0.87) <.001 
   
quintiles2 7906 6% 0.85 (0.73,0.98) 0.028 
   
quintiles3 6232 7% 1.04 (0.90,1.21) 0.598 
   
quintiles4 5696 7% 1.02 (0.88,1.19) 0.803 
   
quintiles5 (farthest) 4520 7% ref 
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